RNS Number: 5075 M Silence Therapeutics PLC 16 September 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 50,000 new ordinary shares of 5 p each following the exercise of share options under the...
Silence Therapeutics Plc (SLN.L) Announced, in its interim results for the six months ended 30 June 2019, that loss before tax stood at £9.6 million compared to a loss of £9.8 million reported in the previous year. The basic loss per share stood at 11.5p compared to loss of 12.4p in the previous year. The company’s cash and cash equivalents stood at £11.5 million (2018: £29.3 million).
RNS Number: 0459 M Silence Therapeutics PLC 12 September 2019. Interim results for the six months ended 30 June 2019. LONDON, Silence Therapeutics, PLC, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces its unaudited interim results for the half year to 30 June 2019..
RNS Number: 2389 K Silence Therapeutics PLC 27 August 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7785 J Silence Therapeutics PLC 21 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 100,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 5319 J Silence Therapeutics PLC 19 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 82,375 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 1012 J Silence Therapeutics PLC 15 August 2019 Silence Therapeutics Notice of Half Year Results and R&D Day. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, will announce results for the half year ending 30 June 2019, at 7:00am BST on Thursday 12...
RNS Number: 7917 I Silence Therapeutics PLC 13 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that yesterday it issued and allotted 200,000 new ordinary shares of 5 p each following the exercise of share options under the...
RNS Number: 4657 I Silence Therapeutics PLC 08 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 40,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 2860 I Silence Therapeutics PLC 07 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 20,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 1162 I Silence Therapeutics PLC 06 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 6,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
Silence Therapeutics Plc (SLN.L) Announced that Jørgen Wittendorff has been appointed to the new role of Head of Manufacturing at Silence Therapeutics. Joining the company's senior management team, he will be responsible for the process development and manufacturing of siRNA therapeutic products for clinical trials and, ultimately, commercial use.
LONDON, Silence Therapeutics, PLC, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that Jørgen Wittendorff has been appointed to the new role of Head of Manufacturing at Silence Therapeutics. Most recently, he was Senior Director, CMC Manufacturing and Product Supply...
RNS Number: 6322 H Silence Therapeutics PLC 01 August 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3411 H Silence Therapeutics PLC 31 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2669 H Silence Therapeutics PLC 30 July 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 100,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
Silence Therapeutics Plc (SLN.L) Announced that further to the announcements on 18 July 2019 detailing the Company's collaboration with and equity investment by Mallinckrodt plc (NYSE: MNK), Steven Romano, MD, has today joined the Board of Silence as a Non-Executive Director.
RNS Number: 9484 G Silence Therapeutics PLC 29 July 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that further to the announcements on 18 July 2019 detailing the Company's collaboration with and equity investment by...
RNS Number: 9062 G Silence Therapeutics PLC 26 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7475 G Silence Therapeutics PLC 25 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    71.07M

Classification

Market Indices-

Locations

HQ
72 Hammersmith Road
London
W14 8TH
Watchlist